Ahmad W. Hajjar
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Ahmad W. Hajjar has a total of 26 co-authors. Here are the top co-authors by number of shared publications:
- Ghaith K. Mansour
College of Pharmacy, Alfaisal University, Riyadh 11533, Saudi Arabia
10 shared publications - Olena Bolgova
College of Medicine, Alfaisal University, Riyadh 11533, Saudi Arabia
4 shared publications - Volodymyr Mavrych
College of Medicine, Alfaisal University, Riyadh 11533, Saudi Arabia
4 shared publications Ghaith K. Mansour
College of Pharmacy, Alfaisal University, Riyadh, Saudi Arabia
2 shared publications- Leen Alangari
College of Medicine, Princess Nourah bint Abdulrahman University, Riyadh 11671, Saudi Arabia
2 shared publications - Leen Khosyfan
College of Medicine, Princess Nourah bint Abdulrahman University, Riyadh 11671, Saudi Arabia
2 shared publications
Latest Publications
- Open Access
- 4 July 2026
- Published by MDPI AG in Medical Sciences
- Vol. 14 (3) , 375
Laparoscopic Diaphragmatic Pacing in Spinal Cord Injury Patients with Respiratory Failure: A Saudi Arabian Experience
Background/Objectives: Cervical spinal cord injury (SCI) carries a significant burden in Saudi Arabia, frequently resulting in permanent ventilator dependence and high morbidity. While laparoscopic diaphragmatic pacing (DP) has emerged as an alternative to long-term mechanical ventilation (MV) globally, regional evidence regarding its application within the Middle East remains limited. This study evaluates a single-center cohort of ventilator-dependent cervical SCI patients undergoing laparoscopic DP. Methods: We conducted a retrospective analysis of all ventilator-dependent patients with cervical SCI admitted to a tertiary hospital in Riyadh between 2012 and 2024 who underwent laparoscopic DP after failing traditional weaning attempts. Inclusion criteria required at least 3 months of MV dependence, intraoperative diaphragmatic stimulability and a minimum one-year follow-up post-implantation. Across the entire cohort, the long-term follow-up duration reached a median of 60.0 months (interquartile range [IQR]: 36.0–84.0 months; range: 12.0–120.0 months). Results: Out of 30 initial candidates with cervical SCI, 28 patients (22 males, 6 females; median age 24.0 years (interquartile range [IQR]: 15.0–33.0 years)) were included. Patients had been on MV for a median of 13.0 months (IQR: 10.5–16.0 months) prior to the procedure. Utilizing a combined weaning success rate (complete or partial weaning), 26 patients (92.86%; 95% CI: 77.42–98.01%) were successfully transitioned to the pacing protocol, while 2 patients (7.14%) experienced DP failure. Complete (24 h) daily MV independence was achieved by 18 patients (64.29%), and partial weaning (≥4 h/day of MV-free time) was achieved by 8 patients (28.57%). Age at the time of injury ranged from 5 to 62 years. No major intraoperative or postoperative complications occurred. Minor exit-site skin irritation was observed in 3 patients (10.71%), all of which resolved completely with conservative local care alone without requiring antibiotic therapy. Conclusions: In this selected single-center Saudi cohort of ventilator-dependent cervical SCI patients, laparoscopic DP was feasible and was associated with high rates of partial or complete ventilator-free breathing. Larger prospective multicenter studies with standardized selection criteria, safety reporting, respiratory outcomes, quality-of-life measures, and longer follow-up are needed.
- 4 July 2026
- Published by MDPI AG in Medical Sciences
- Vol. 14 (3) , 375
Open AccessLaparoscopic Diaphragmatic Pacing in Spinal Cord Injury Patients with Respiratory Failure: A Saudi Arabian Experience
Background/Objectives: Cervical spinal cord injury (SCI) carries a significant burden in Saudi Arabia, frequently resulting in permanent ventilator dependence and high morbidity. While laparoscopic diaphragmatic pacing (DP) has emerged as an alternative to long-term mechanical ventilation (MV) globally, regional evidence regarding its application within the Middle East remains limited. This study evaluates a single-center cohort of ventilator-dependent cervical SCI patients undergoing laparoscopic DP. Methods: We conducted a retrospective analysis of all ventilator-dependent patients with cervical SCI admitted to a tertiary hospital in Riyadh between 2012 and 2024 who underwent laparoscopic DP after failing traditional weaning attempts. Inclusion criteria required at least 3 months of MV dependence, intraoperative diaphragmatic stimulability and a minimum one-year follow-up post-implantation. Across the entire cohort, the long-term follow-up duration reached a median of 60.0 months (interquartile range [IQR]: 36.0–84.0 months; range: 12.0–120.0 months). Results: Out of 30 initial candidates with cervical SCI, 28 patients (22 males, 6 females; median age 24.0 years (interquartile range [IQR]: 15.0–33.0 years)) were included. Patients had been on MV for a median of 13.0 months (IQR: 10.5–16.0 months) prior to the procedure. Utilizing a combined weaning success rate (complete or partial weaning), 26 patients (92.86%; 95% CI: 77.42–98.01%) were successfully transitioned to the pacing protocol, while 2 patients (7.14%) experienced DP failure. Complete (24 h) daily MV independence was achieved by 18 patients (64.29%), and partial weaning (≥4 h/day of MV-free time) was achieved by 8 patients (28.57%). Age at the time of injury ranged from 5 to 62 years. No major intraoperative or postoperative complications occurred. Minor exit-site skin irritation was observed in 3 patients (10.71%), all of which resolved completely with conservative local care alone without requiring antibiotic therapy. Conclusions: In this selected single-center Saudi cohort of ventilator-dependent cervical SCI patients, laparoscopic DP was feasible and was associated with high rates of partial or complete ventilator-free breathing. Larger prospective multicenter studies with standardized selection criteria, safety reporting, respiratory outcomes, quality-of-life measures, and longer follow-up are needed.
- Open Access
- 25 June 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (13) , 5734
Xanomeline–Trospium Validates Muscarinic Agonism as an Effective Non-Dopaminergic Treatment for Schizophrenia
Schizophrenia remains a debilitating global health challenge where pharmacologic treatment has been stagnant for over seventy years, relying almost exclusively on the blockade of dopamine receptors. While this mechanism controls positive psychosis, it frequently fails to address negative symptoms or cognitive impairment and carries a significant burden of metabolic and motor adverse effects. This review evaluates the scientific and clinical validation of xanomeline–trospium (Cobenfy®; investigational name KarXT), the first approved antipsychotic with a completely non-dopaminergic mechanism of action. We synthesize data ranging from the unique structural biology of the bitopic M1/M4 muscarinic receptor agonist xanomeline to the pharmacokinetic innovation of using the peripheral antagonist trospium chloride to mitigate systemic toxicity. Comprehensive analyses of the EMERGENT clinical trial program demonstrate that this combination significantly reduces heterogeneous schizophrenia symptoms with a safety profile distinct from current standards of care, specifically avoiding weight gain and extrapyramidal movement disorders. Furthermore, we contrast this success with the recent failures of other novel mechanisms and explore the potential for precision medicine through the identification of muscarinic receptor deficit biotypes. We conclude that M1/M4 muscarinic receptor agonism represents an important advance toward circuit-based therapeutics that may help overcome some of the limitations inherent to dopamine-centered pharmacotherapy.
- 25 June 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (13) , 5734
Open AccessXanomeline–Trospium Validates Muscarinic Agonism as an Effective Non-Dopaminergic Treatment for Schizophrenia
Schizophrenia remains a debilitating global health challenge where pharmacologic treatment has been stagnant for over seventy years, relying almost exclusively on the blockade of dopamine receptors. While this mechanism controls positive psychosis, it frequently fails to address negative symptoms or cognitive impairment and carries a significant burden of metabolic and motor adverse effects. This review evaluates the scientific and clinical validation of xanomeline–trospium (Cobenfy®; investigational name KarXT), the first approved antipsychotic with a completely non-dopaminergic mechanism of action. We synthesize data ranging from the unique structural biology of the bitopic M1/M4 muscarinic receptor agonist xanomeline to the pharmacokinetic innovation of using the peripheral antagonist trospium chloride to mitigate systemic toxicity. Comprehensive analyses of the EMERGENT clinical trial program demonstrate that this combination significantly reduces heterogeneous schizophrenia symptoms with a safety profile distinct from current standards of care, specifically avoiding weight gain and extrapyramidal movement disorders. Furthermore, we contrast this success with the recent failures of other novel mechanisms and explore the potential for precision medicine through the identification of muscarinic receptor deficit biotypes. We conclude that M1/M4 muscarinic receptor agonism represents an important advance toward circuit-based therapeutics that may help overcome some of the limitations inherent to dopamine-centered pharmacotherapy.
- Open Access
- 22 April 2026
- Published by Springer Nature in Schizophrenia
- Vol. 12 (1)
From neuroinflammation to neural inference: computational psychiatry meets precision medicine
Psychosis spectrum disorders exhibit substantial clinical variability, necessitating novel frameworks that transcend traditional symptomatic classification. While polygenic risk accounts for significant heritability, the precise mechanisms translating genetic vulnerability into clinical illness remain elusive. An increasingly compelling hypothesis suggests that immune-related abnormalities link genetic risk with environmental stressors to precipitate neural dysfunction. This review integrates neuroimmunology and computational psychiatry to advance mechanism-driven precision medicine by connecting specific molecular dysfunctions to high-level information processing deficits. We synthesize evidence demonstrating that genetic and environmental risks converge on immune pathways—particularly microglial dysfunction and aberrant synaptic pruning. Functionally, we propose this pathology drives fundamental information processing errors, including maladaptive prior beliefs and reduced sensory precision. Here we highlight the necessity of multi-modal biomarkers and real-time digital phenotyping to stratify patients based on underlying neuro-immune endotypes. Finally, we address the critical challenge of algorithmic bias, emphasizing that proactive, standards-based strategies are required to ensure computational models are equitable and generalizable across diverse global populations. This integrated roadmap offers a path toward a truly personalized, biologically grounded psychiatry.
- 22 April 2026
- Published by Springer Nature in Schizophrenia
- Vol. 12 (1)
Open AccessFrom neuroinflammation to neural inference: computational psychiatry meets precision medicine
Psychosis spectrum disorders exhibit substantial clinical variability, necessitating novel frameworks that transcend traditional symptomatic classification. While polygenic risk accounts for significant heritability, the precise mechanisms translating genetic vulnerability into clinical illness remain elusive. An increasingly compelling hypothesis suggests that immune-related abnormalities link genetic risk with environmental stressors to precipitate neural dysfunction. This review integrates neuroimmunology and computational psychiatry to advance mechanism-driven precision medicine by connecting specific molecular dysfunctions to high-level information processing deficits. We synthesize evidence demonstrating that genetic and environmental risks converge on immune pathways—particularly microglial dysfunction and aberrant synaptic pruning. Functionally, we propose this pathology drives fundamental information processing errors, including maladaptive prior beliefs and reduced sensory precision. Here we highlight the necessity of multi-modal biomarkers and real-time digital phenotyping to stratify patients based on underlying neuro-immune endotypes. Finally, we address the critical challenge of algorithmic bias, emphasizing that proactive, standards-based strategies are required to ensure computational models are equitable and generalizable across diverse global populations. This integrated roadmap offers a path toward a truly personalized, biologically grounded psychiatry.
- Open Access
- 21 April 2026
- Published by Frontiers Media SA in Frontiers in Medicine
- Vol. 13, 1748453
Beyond attenuation: a translational review of curative-intent pharmacological targets in idiopathic pulmonary fibrosis
Idiopathic Pulmonary Fibrosis (IPF) is a progressive, fatal lung disease with a median survival of 3–5 years, driven by a profound unmet medical need. The current standard-of-care agents, pirfenidone and nintedanib, merely slow disease progression and are burdened by significant toxicity. This review synthesizes the basic, clinical, and translational evolution of novel pharmacological approaches for IPF, analyzing the critical lessons from recent high-profile clinical trial failures and successes. This review followed a narrative, analytical methodology, examining key Phase 2 and 3 clinical trials to identify a “failure-to-refinement” trajectory in drug development. Analysis reveals that targeting broad-spectrum enzymes (e.g., autotaxin via ziritaxestat) or downstream effectors (e.g., Connective Tissue Growth Factor (CTGF) via pamrevlumab) has failed, likely due to mechanistic redundancy or insufficient target engagement. In contrast, highly specific, next-generation inhibitors targeting upstream signal initiation points such as the lysophosphatidic acid receptor 1 (LPAR1) (admilparant) and local αv β 6 integrin-mediated activation of transforming growth factor-beta (TGF-β) (bexotegrast) have yielded promising Phase 2 data, demonstrating a sophisticated translational learning loop. Furthermore, the geroscience approach targeting cellular senescence (dasatinib/quercetin) has introduced a controversial new paradigm, while the recent approval of nerandomilast (a phosphodiesterase 4B (PDE4B) inhibitor) establishes a new therapeutic class. The IPF pipeline has matured, moving from broad attenuation toward specific, mechanism-based inhibition. This shift, informed by interpreting trial failures, is guiding the development of therapies toward disease modification and combination strategies, offering a tangible path toward curative-intent treatments.
- 21 April 2026
- Published by Frontiers Media SA in Frontiers in Medicine
- Vol. 13, 1748453
Open AccessBeyond attenuation: a translational review of curative-intent pharmacological targets in idiopathic pulmonary fibrosis
Idiopathic Pulmonary Fibrosis (IPF) is a progressive, fatal lung disease with a median survival of 3–5 years, driven by a profound unmet medical need. The current standard-of-care agents, pirfenidone and nintedanib, merely slow disease progression and are burdened by significant toxicity. This review synthesizes the basic, clinical, and translational evolution of novel pharmacological approaches for IPF, analyzing the critical lessons from recent high-profile clinical trial failures and successes. This review followed a narrative, analytical methodology, examining key Phase 2 and 3 clinical trials to identify a “failure-to-refinement” trajectory in drug development. Analysis reveals that targeting broad-spectrum enzymes (e.g., autotaxin via ziritaxestat) or downstream effectors (e.g., Connective Tissue Growth Factor (CTGF) via pamrevlumab) has failed, likely due to mechanistic redundancy or insufficient target engagement. In contrast, highly specific, next-generation inhibitors targeting upstream signal initiation points such as the lysophosphatidic acid receptor 1 (LPAR1) (admilparant) and local αv β 6 integrin-mediated activation of transforming growth factor-beta (TGF-β) (bexotegrast) have yielded promising Phase 2 data, demonstrating a sophisticated translational learning loop. Furthermore, the geroscience approach targeting cellular senescence (dasatinib/quercetin) has introduced a controversial new paradigm, while the recent approval of nerandomilast (a phosphodiesterase 4B (PDE4B) inhibitor) establishes a new therapeutic class. The IPF pipeline has matured, moving from broad attenuation toward specific, mechanism-based inhibition. This shift, informed by interpreting trial failures, is guiding the development of therapies toward disease modification and combination strategies, offering a tangible path toward curative-intent treatments.
- Open Access
- 16 March 2026
- Published by MDPI AG in Current Oncology
- Vol. 33 (3) , 169
Knowledge and Awareness of the General Public on Lung Cancer Screening Modalities and Lung Cancer Preventive Methods in Riyadh, Saudi Arabia
Lung cancer remains the leading cause of cancer-related mortality globally and is often diagnosed at advanced stages in Saudi Arabia. This cross-sectional study aimed to quantify public awareness and knowledge of lung cancer screening (LCS) using LDCT and identify barriers to its implementation in Riyadh. A validated 24-item questionnaire was administered to 452 participants to assess demographic factors, smoking history, and LCS knowledge. Results revealed that only 30.1% of participants had heard of LCS, and 50.2% demonstrated “poor” knowledge scores (mean score 11.0 ± 4.97). Higher knowledge scores were significantly associated with being female, having a bachelor’s degree or higher, and being a non-smoker. While 78.1% expressed willingness to undergo screening, the most significant barrier was a lack of knowledge about the test (44.1%), followed by concerns regarding radiation exposure (36.1%). Conversely, a healthcare provider’s recommendation was identified as the primary motivator for 53.3% of respondents. These findings highlight a critical “awareness–willingness” gap. While public willingness is high, this should not be misconstrued as systemic preparedness; substantial educational and structural gaps remain that must be bridged before national implementation can be considered feasible. We conclude that while public willingness is high, successful implementation requires a transition toward organized invitation systems and the use of multifactorial risk profiles. Integrating epidemiological evidence with proactive policy design is essential to ensure that the national program avoids systematic under- or over-inclusion and remains effective for all demographics.
- 16 March 2026
- Published by MDPI AG in Current Oncology
- Vol. 33 (3) , 169
Open AccessKnowledge and Awareness of the General Public on Lung Cancer Screening Modalities and Lung Cancer Preventive Methods in Riyadh, Saudi Arabia
Lung cancer remains the leading cause of cancer-related mortality globally and is often diagnosed at advanced stages in Saudi Arabia. This cross-sectional study aimed to quantify public awareness and knowledge of lung cancer screening (LCS) using LDCT and identify barriers to its implementation in Riyadh. A validated 24-item questionnaire was administered to 452 participants to assess demographic factors, smoking history, and LCS knowledge. Results revealed that only 30.1% of participants had heard of LCS, and 50.2% demonstrated “poor” knowledge scores (mean score 11.0 ± 4.97). Higher knowledge scores were significantly associated with being female, having a bachelor’s degree or higher, and being a non-smoker. While 78.1% expressed willingness to undergo screening, the most significant barrier was a lack of knowledge about the test (44.1%), followed by concerns regarding radiation exposure (36.1%). Conversely, a healthcare provider’s recommendation was identified as the primary motivator for 53.3% of respondents. These findings highlight a critical “awareness–willingness” gap. While public willingness is high, this should not be misconstrued as systemic preparedness; substantial educational and structural gaps remain that must be bridged before national implementation can be considered feasible. We conclude that while public willingness is high, successful implementation requires a transition toward organized invitation systems and the use of multifactorial risk profiles. Integrating epidemiological evidence with proactive policy design is essential to ensure that the national program avoids systematic under- or over-inclusion and remains effective for all demographics.
- Open Access
- 23 December 2025
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (1) , 158
Redox Modulation in Hepatic Fibrosis: Translating NOX1/4 Inhibition to Therapy
Chronic liver disease (CLD) encompasses a spectrum of progressive disorders, including metabolic dysfunction steatotic-associated liver disease (MASLD) and primary biliary cholangitis (PBC), which together represent a significant global health burden with few effective therapeutic options. The fibrogenic process, common to most forms of CLD, is driven by a complex interplay of cellular stress, inflammation, and wound-healing responses. Nicotinamide adenine dinucleotide phosphate oxidase isoforms 1 and 4 (NOX1 and NOX4) have emerged as key enzymatic sources of reactive oxygen species (ROS), serving as central mediators of hepatic oxidative stress, fibrogenesis, and inflammation. Setanaxib is a first-in-class, orally bioavailable, selective dual inhibitor of NOX1 and NOX4 that has progressed to clinical evaluation. This review synthesizes current knowledge on the molecular pharmacology of the NOX1/4 axis, preclinical evidence from translational models, and clinical trial outcomes to critically assess the therapeutic potential of targeted NOX inhibition in hepatic fibrosis. By attenuating hepatic stellate cell activation, modulating TGF-β signaling, reducing extracellular matrix (ECM) deposition, and regulating hepatic macrophage polarization, setanaxib exhibits pleiotropic antifibrotic effects. The compound also demonstrates favorable pharmacokinetic properties and a good safety profile in patients with PBC, with emerging evidence suggesting meaningful improvements in fatigue and quality of life. Finally, we examine the complex, and sometimes paradoxical, roles of NOX4 in liver pathophysiology, compare the evolving therapeutic landscape with other approaches such as farnesoid X receptor (FXR) agonists, and propose future paradigms integrating artificial intelligence–driven predictive modeling to optimize patient stratification and therapeutic response in this new era of redox-targeted hepatoprotective therapy.
- 23 December 2025
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (1) , 158
Open AccessRedox Modulation in Hepatic Fibrosis: Translating NOX1/4 Inhibition to Therapy
Chronic liver disease (CLD) encompasses a spectrum of progressive disorders, including metabolic dysfunction steatotic-associated liver disease (MASLD) and primary biliary cholangitis (PBC), which together represent a significant global health burden with few effective therapeutic options. The fibrogenic process, common to most forms of CLD, is driven by a complex interplay of cellular stress, inflammation, and wound-healing responses. Nicotinamide adenine dinucleotide phosphate oxidase isoforms 1 and 4 (NOX1 and NOX4) have emerged as key enzymatic sources of reactive oxygen species (ROS), serving as central mediators of hepatic oxidative stress, fibrogenesis, and inflammation. Setanaxib is a first-in-class, orally bioavailable, selective dual inhibitor of NOX1 and NOX4 that has progressed to clinical evaluation. This review synthesizes current knowledge on the molecular pharmacology of the NOX1/4 axis, preclinical evidence from translational models, and clinical trial outcomes to critically assess the therapeutic potential of targeted NOX inhibition in hepatic fibrosis. By attenuating hepatic stellate cell activation, modulating TGF-β signaling, reducing extracellular matrix (ECM) deposition, and regulating hepatic macrophage polarization, setanaxib exhibits pleiotropic antifibrotic effects. The compound also demonstrates favorable pharmacokinetic properties and a good safety profile in patients with PBC, with emerging evidence suggesting meaningful improvements in fatigue and quality of life. Finally, we examine the complex, and sometimes paradoxical, roles of NOX4 in liver pathophysiology, compare the evolving therapeutic landscape with other approaches such as farnesoid X receptor (FXR) agonists, and propose future paradigms integrating artificial intelligence–driven predictive modeling to optimize patient stratification and therapeutic response in this new era of redox-targeted hepatoprotective therapy.
- Open Access
- 21 December 2025
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (1) , 84
Hormonal and Behavioral Consequences of Social Isolation and Loneliness: Neuroendocrine Mechanisms and Clinical Implications
Social isolation and loneliness represent critical psychosocial stressors associated with profound hormonal dysregulation and adverse behavioral outcomes. This review synthesizes current evidence on neuroendocrine mechanisms linking perceived and objective social disconnection to health consequences, emphasizing hypothalamic–pituitary–adrenal axis dysfunction, altered glucocorticoid signaling, and inflammatory pathways. Loneliness activates conserved transcriptional responses with upregulated proinflammatory gene expression and downregulated antiviral responses, mediated through sustained cortisol elevation and glucocorticoid resistance. Neural circuit alterations in reward processing, particularly the ventral tegmental area-nucleus accumbens pathway, contribute to anhedonia, social withdrawal, and cognitive decline. Sex differences in neuroendocrine responses reveal distinct hormonal profiles and circuit-specific adaptations. Emerging interventions targeting oxytocin and arginine vasopressin systems, alongside behavioral approaches addressing loneliness-induced cognitive biases, show promise. Critical research gaps include a mechanistic understanding of epigenetic modifications, sex-specific therapeutic responses, and translational applications across diverse populations. Understanding the endocrine–behavior interface in social disconnection offers opportunities for targeted interventions addressing this growing public health challenge.
- 21 December 2025
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (1) , 84
Open AccessHormonal and Behavioral Consequences of Social Isolation and Loneliness: Neuroendocrine Mechanisms and Clinical Implications
Social isolation and loneliness represent critical psychosocial stressors associated with profound hormonal dysregulation and adverse behavioral outcomes. This review synthesizes current evidence on neuroendocrine mechanisms linking perceived and objective social disconnection to health consequences, emphasizing hypothalamic–pituitary–adrenal axis dysfunction, altered glucocorticoid signaling, and inflammatory pathways. Loneliness activates conserved transcriptional responses with upregulated proinflammatory gene expression and downregulated antiviral responses, mediated through sustained cortisol elevation and glucocorticoid resistance. Neural circuit alterations in reward processing, particularly the ventral tegmental area-nucleus accumbens pathway, contribute to anhedonia, social withdrawal, and cognitive decline. Sex differences in neuroendocrine responses reveal distinct hormonal profiles and circuit-specific adaptations. Emerging interventions targeting oxytocin and arginine vasopressin systems, alongside behavioral approaches addressing loneliness-induced cognitive biases, show promise. Critical research gaps include a mechanistic understanding of epigenetic modifications, sex-specific therapeutic responses, and translational applications across diverse populations. Understanding the endocrine–behavior interface in social disconnection offers opportunities for targeted interventions addressing this growing public health challenge.
- Open Access
- 16 December 2025
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 14 (24) , 8896
The Precision Revolution in Hematologic Malignancies: A Decade of Transformative Immunotherapies and Targeted Agents
This review describes the dramatic transformation that has occurred in the last ten years in the therapeutic landscape for hematologic malignancies, such as leukemias, lymphomas, myelomas, and myelodysplastic syndromes. Treatment paradigms have quickly changed from depending solely on cytotoxic chemotherapy to embracing precision medicine, driven by a previously unprecedented understanding of disease biology and precise molecular changes. The development of powerful immunotherapies (such as CAR T-cell therapy and bispecific antibodies) and innovative targeted agents (like BTK inhibitors, BCL-2 inhibitors, and immunomodulatory medications) is at the heart of this revolution. In addition to evaluating new and synergistic combination strategies, this paper examines the clinical utility, efficacy, and recent developments of these novel agents. It also addresses important issues like managing acquired drug resistance, minimizing financial burden, and adapting clinical trial designs to keep pace with innovation. These advancements are collectively redefining clinical practice, leading to deeper and more durable responses, and significantly improving the prognosis and quality of life for patients.
- 16 December 2025
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 14 (24) , 8896
Open AccessThe Precision Revolution in Hematologic Malignancies: A Decade of Transformative Immunotherapies and Targeted Agents
This review describes the dramatic transformation that has occurred in the last ten years in the therapeutic landscape for hematologic malignancies, such as leukemias, lymphomas, myelomas, and myelodysplastic syndromes. Treatment paradigms have quickly changed from depending solely on cytotoxic chemotherapy to embracing precision medicine, driven by a previously unprecedented understanding of disease biology and precise molecular changes. The development of powerful immunotherapies (such as CAR T-cell therapy and bispecific antibodies) and innovative targeted agents (like BTK inhibitors, BCL-2 inhibitors, and immunomodulatory medications) is at the heart of this revolution. In addition to evaluating new and synergistic combination strategies, this paper examines the clinical utility, efficacy, and recent developments of these novel agents. It also addresses important issues like managing acquired drug resistance, minimizing financial burden, and adapting clinical trial designs to keep pace with innovation. These advancements are collectively redefining clinical practice, leading to deeper and more durable responses, and significantly improving the prognosis and quality of life for patients.
- Open Access
- 8 December 2025
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 26 (24) , 11843
Neurovascular Dysfunction and Glymphatic Impairment: An Unexplored Therapeutic Frontier in Neurodegeneration
Neurodegenerative diseases pose major clinical challenges partly due to the underappreciation of the brain’s vascular and clearance systems. Evidence suggests that neurovascular dysfunction and glymphatic impairment are early contributors to disease onset, preceding established markers such as protein aggregation. This review synthesizes recent advances in understanding how disruption of the neurovascular unit (NVU) and glymphatic pathways contributes to neurodegeneration. We analyzed published literature documenting the temporal relationship between vascular dysfunction, glymphatic clearance impairment, and subsequent neurodegenerative pathology, with a focus on identifying therapeutic targets within this axis. Current research demonstrates that blood-brain barrier BBB breakdown, pericyte dysfunction, and compromised cerebral perfusion precede protein aggregation in multiple neurodegenerative disorders. Glymphatic dysfunction, characterized by aquaporin-4 (AQP4) depolarization and abnormalities in meningeal lymphatic vessels, impairs the clearance of neurotoxic metabolites. Novel therapeutic opportunities include the preservation of pericyte function, restoration of AQP4 polarity, enhancement of meningeal lymphatic drainage via vascular endothelial growth factor-C (VEGF-C)/vascular endothelial growth factor receptor-3 VEGFR-3 signaling, and targeted modulation of microRNA and complement pathways that regulate neuroinflammation. By targeting the earliest vascular and glymphatic disruptions, emerging therapeutic strategies may halt or delay disease progression before irreversible neuronal loss occurs. This neurovascular-glymphatic approach represents an unexplored frontier that complements traditional protein-centric therapeutic paradigms, offering new possibilities for early intervention in neurodegenerative disorders.
- 8 December 2025
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 26 (24) , 11843
Open AccessNeurovascular Dysfunction and Glymphatic Impairment: An Unexplored Therapeutic Frontier in Neurodegeneration
Neurodegenerative diseases pose major clinical challenges partly due to the underappreciation of the brain’s vascular and clearance systems. Evidence suggests that neurovascular dysfunction and glymphatic impairment are early contributors to disease onset, preceding established markers such as protein aggregation. This review synthesizes recent advances in understanding how disruption of the neurovascular unit (NVU) and glymphatic pathways contributes to neurodegeneration. We analyzed published literature documenting the temporal relationship between vascular dysfunction, glymphatic clearance impairment, and subsequent neurodegenerative pathology, with a focus on identifying therapeutic targets within this axis. Current research demonstrates that blood-brain barrier BBB breakdown, pericyte dysfunction, and compromised cerebral perfusion precede protein aggregation in multiple neurodegenerative disorders. Glymphatic dysfunction, characterized by aquaporin-4 (AQP4) depolarization and abnormalities in meningeal lymphatic vessels, impairs the clearance of neurotoxic metabolites. Novel therapeutic opportunities include the preservation of pericyte function, restoration of AQP4 polarity, enhancement of meningeal lymphatic drainage via vascular endothelial growth factor-C (VEGF-C)/vascular endothelial growth factor receptor-3 VEGFR-3 signaling, and targeted modulation of microRNA and complement pathways that regulate neuroinflammation. By targeting the earliest vascular and glymphatic disruptions, emerging therapeutic strategies may halt or delay disease progression before irreversible neuronal loss occurs. This neurovascular-glymphatic approach represents an unexplored frontier that complements traditional protein-centric therapeutic paradigms, offering new possibilities for early intervention in neurodegenerative disorders.
- Open Access
- 4 December 2025
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 14 (23) , 8594
Mavacamten for Obstructive Hypertrophic Cardiomyopathy: Targeting Sarcomeric Hypercontractility with Demonstrated Long-Term Safety and Efficacy—A Narrative Review
Hypertrophic cardiomyopathy (HCM) is the most prevalent hereditary cardiovascular disorder characterized by unexplained left ventricular hypertrophy, sarcomeric hypercontractility, and dynamic left ventricular outflow tract (LVOT) obstruction in approximately 70% of patients. Current therapies predominantly offer symptomatic relief through indirect modulation of cardiac function, leaving the underlying molecular pathophysiology unaddressed. Mavacamten, a first-in-class, selective allosteric inhibitor of β-cardiac myosin ATPase, exemplifies a precision pharmacological approach by directly targeting the sarcomeric hypercontractility fundamental to obstructive HCM (oHCM). This review synthesizes extensive clinical and preclinical evidence delineating mavacamten’s mechanism of action, pharmacokinetics influenced by CYP2C19 genotype variability, and its demonstrated efficacy and long-term safety in improving functional capacity, symptom burden, and cardiac remodeling. Landmark trials, including EXPLORER-HCM and MAVERICK-HCM, underscore mavacamten’s ability to reduce LVOT gradients, enhance diastolic function, and lower cardiac biomarkers, heralding a paradigm shift from symptomatic management to disease-modifying therapy. Despite current knowledge gaps in long-term outcomes and diverse population responses, mavacamten establishes a critical foundation for molecularly targeted therapeutics in HCM and broader cardiomyopathies.
- 4 December 2025
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 14 (23) , 8594
Open AccessMavacamten for Obstructive Hypertrophic Cardiomyopathy: Targeting Sarcomeric Hypercontractility with Demonstrated Long-Term Safety and Efficacy—A Narrative Review
Hypertrophic cardiomyopathy (HCM) is the most prevalent hereditary cardiovascular disorder characterized by unexplained left ventricular hypertrophy, sarcomeric hypercontractility, and dynamic left ventricular outflow tract (LVOT) obstruction in approximately 70% of patients. Current therapies predominantly offer symptomatic relief through indirect modulation of cardiac function, leaving the underlying molecular pathophysiology unaddressed. Mavacamten, a first-in-class, selective allosteric inhibitor of β-cardiac myosin ATPase, exemplifies a precision pharmacological approach by directly targeting the sarcomeric hypercontractility fundamental to obstructive HCM (oHCM). This review synthesizes extensive clinical and preclinical evidence delineating mavacamten’s mechanism of action, pharmacokinetics influenced by CYP2C19 genotype variability, and its demonstrated efficacy and long-term safety in improving functional capacity, symptom burden, and cardiac remodeling. Landmark trials, including EXPLORER-HCM and MAVERICK-HCM, underscore mavacamten’s ability to reduce LVOT gradients, enhance diastolic function, and lower cardiac biomarkers, heralding a paradigm shift from symptomatic management to disease-modifying therapy. Despite current knowledge gaps in long-term outcomes and diverse population responses, mavacamten establishes a critical foundation for molecularly targeted therapeutics in HCM and broader cardiomyopathies.